Document is current

Article History

Received: 30 June 2020

Accepted: 21 December 2020

First Online: 8 February 2021

Change Date: 10 April 2021

Change Type: Update

Change Details: The paper was amended to add the OA funding note.

Ethics approval and consent to participate

: Research was approved by the medical ethical committee of the VU University medical center and Lund University and was in accordance with the Helsinki Declaration act of 1975. All subjects provided written informed consent to use their medical data and biomaterials for scientific research.

: Not applicable.

: OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche.PS has received consultancy/speaker fees (paid to the institution) from Biogen, Novartis Cardiology, Genentech and AC Immune. He is PI of studies with Vivoryon, EIP Pharma, IONIS, CogRx, AC Immune and FUJI-film/Toyama. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). CET has a collaboration contract with ADx Neurosciences and performed contract research or received grants from Probiodrug, AC Immune, Biogen-Esai, CogRx, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio and Roche. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).